SAL0140
/ Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 07, 2025
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
(clinicaltrials.gov)
- P1 | N=82 | Recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1